abstract | Tumor necrosis factor (TNF) blockers are widely used to treat rheumatoid arthritis and other chronic inflammatory diseases. Many studies have demonstrated an increased risk of opportunistic infections such as tuberculosis and fungal infection in patients treated with TNF blockers, which is thought to be related to the primary role of TNF both in host defense and in the immune response. Little is known, however, about the association between TNF blockade and the development of viral infection. Owing to the critical role of TNF in the control of viral infection, depletion of this cytokine with TNF blockers could facilitate the development or reactivation of viral infection. A number of large observational studies have found an increased risk of herpes zoster in patients receiving TNF blockers for the treatment of rheumatoid arthritis. This Review draws attention to the risk of several viral infections, including HIV, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, and human papillomavirus, in patients receiving TNF-blocking therapy for chronic inflammatory conditions. In addition, implications for clinical practice and possible preventative approaches are discussed.
Introduction
tumor necrosis factor (tnF) plays an essential part in host defense and the immune response.
1 tnF receptors (tnFrs) are found on virtually all cell types, and tnF affects a variety of physiologic processes. tnF blockers are an effective treatment for several chronic inflammatory disorders, including rheumatoid arthritis (ra), and the increasingly widespread use of these agents highlights the importance of understanding their safety. much attention has been paid to the risks of opportunistic infection (such as tuberculosis and fungal infections) associated with use of tnF blockers. 2, 3 Conflicting data exist, however, on the association between the use of these agents and serious infections that lead to hospitalization or mortality.
4-6 a recent meta-analysis by Bongartz et al. 7 reported that the number needed to harm for up to 1 year of therapy with infliximab or adalimumab was 59 (95% Ci 39-125) for serious infection. to date, most studies have focused on the risk of bacterial and opportunistic infections, with few assessing a possible association between viral infections and tnFblocking agents. since tnF plays a critical role in the control of viral infection-through the recruitment and activation of macrophages, natural killer cells, t cells, and antigen-presenting cells-the depletion of tnF by treatment with tnF blockers might facilitate the develop ment or reactivation of viral infection.
8,9 this review highlights possible links between tnF blockers and several types of viral infection. the association with viral hepatitis is not included as this has recently been reviewed elsewhere.
10,11
HIV infection although tnF is known to be involved in the pathogenesis of Hiv infection, its exact role is not completely understood.
9 a positive association has been reported between activation of the tnF system in vivo and progression of Hiv-related clinical disease.
12,13 tnF and death receptors such as Fas ligand are directly and in directly involved in the activation of t-cell apoptotic processes in Hiv infection. [14] [15] [16] several studies have proposed an important role for tnFr signaling in the progression of Hiv infection. 14, 16, 17 Both tnFr1 and tnFr2 can induce apoptosis in peripheral CD4 + and CD8 + t cells in Hivinfected patients. 14 Furthermore, serum levels of tnF and tnFr seem to be elevated in patients with Hiv, and could have a critical role in the clinical progression of Hiv infection. 18, 19 Based on the hypothesis that inhibiting circulating tnF could be a therapeutic strategy, walker et al. 20 examined the safety and efficacy of a chimeric antibody against tnF in six patients with Hiv and baseline CD4 + t cell counts of less than 200 per mm 3 . 20 the investigators found no significant changes in CD4 + t cell counts or plasma Hiv rna levels. safety concerns remain, however, including whether the use of tnF blockers further increases the risk of opportunistic infection in Hiv-infected patients, and whether these agents adversely affect the long-term outcome of Hiv infection by further suppressing the host defense system. Data on the safety of tnF blockers for the treatment of chronic inflammatory conditions in Hiv-infected patients are limited and derive mostly from case reports (table 1) . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] the majority of the patients included in these case reports received concomitant, highly active antiretroviral therapy. infliximab infusions, ranging in dose from 2-5 mg/kg, led to marked clinical improvement without associated serious infection or worsening of Hiv infection. [22] [23] [24] [25] 29, 30 Furthermore, no serious infectious complications or increases in the Hiv viral load were noted in patients given etanercept 50 mg weekly or 25 mg twice weekly. [26] [27] [28] 30, 31 successful outcomes with etanercept were even noted in patients with both Hiv and viral hepatitis infection. 27, 28 By contrast, aboulafia et al. 21 reported on a 45 year old Hiv-infected male with psoriatic arthritis (Psa) who died of a severe bacterial infection 4 months following etanercept therapy, despite stable CD4 cell count and viral load. 21 less information is available regarding the safety of adalimumab in Hivinfected patients. three Hiv-positive patients with concomitant Psa in a study by Cepeda et al. 30 achieved a partial clinical response to adalimumab, whereas their CD4 + counts and Hiv viral loads remained stable. whether the relative safety of tnF blocking agents in the cases described above can be generalized to other Hiv-infected patients remains unknown. until there is a better understanding of the long-term safety of tnF blockade in patients with Hiv, clinicians should avoid use of these drugs in this population. in circumstances where tnF blockers are required and no alternative treatment exists, these drugs should be used with extreme caution and CD4 + counts, viral loads, and clinical signs and sy mptoms of infection should be closely monitored.
Varicella-zoster virus infection
varicella-zoster virus (vZv) is the cause of primary varicella (also known as chickenpox), herpes zoster (shingles) and postherpetic neuralgia. in children, primary varicella infection is common and usually benign. How ever, disseminated varicella infection in adults, and particularly in immunocompromised patients, can be severe and potentially fatal. 32 in the general population, the incidence of herpes zoster, which is caused by reactivation of vZv in sensory nerve roots, is reported to be 1.2-4.8 cases per 1,000 person-years. 33, 34 Patients with compromised cell-mediated immunity as a result of aging, use of immuno suppressive agents, or concomitant illness are at an increased risk of developing herpes zoster. 34, 35 the severity of herpes zoster is related to the degree of immuno competence in such indivi duals, which is demon strated by the greater infection severity observed in patients with organ transplantations, lympho proliferative diseases (lPD) or aiDs. 36 a number of commentators have noted that herpes zoster is more common in patients with systemic lupus erythematosus (sle) or ra than in the general population, because of both the impaired immune system in these patients and the medications used to treat these conditions. [37] [38] [39] [40] several case reports and retro spective studies reporting vZv infection in patients who received tnF blocking therapy for inflammatory conditions are listed in table 2. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Data from the Consortium of rheumatology researchers of north america (Corrona) registry showed that vZv infection was the most frequent infection in patients who received methotrexate, tnF blockers or other DmarDs, and accounted for 44% of all cases of opportunistic infection. 53 a retrospective cohort study using data from the us veterans' affairs health system demonstrated an elevated incidence of herpes zoster in patients with ra-9.96 cases per 1,000 patient-years. 54 Correlates of herpes zoster included old age, use of glucocorticoids or DmarDs (including methotrexate, leflunomide, azathioprine, cyclophosphamide, ciclosporin, anakinra and tnF blockers), and the presence of malignancy, chronic lung disease, renal failure, or liver disease. of 3,661 patients treated with tnF blockers, 96 developed herpes zoster. among the tnF blockers used, etanercept (hazard ratio [Hr] 0.62, 95% Ci 0.40-0.95) and adalimumab (Hr 0.53, 95% Ci 0.31-0.91) were associated with a lower risk of herpes zoster than infliximab (Hr 1.32, 95% Ci 0.85-2.03). 54 By contrast, a prospective study using data from the German biologics register reported a significantly increased risk of herpes zoster in patients receiving infliximab and adalimumab (Hr, 1.82, 95% Ci 1.05-3.15) compared with etanercept, even after adjusting for age, severity of ra, and glucocorticoid use. 41 notably, no significant association was found for etanercept use (Hr 1.36, 95% Ci 0.73-2.55).
as noted in table 2, serious morbidity and mortality from vZv infection can occur in patients who receive tnF blocking therapy. of the six cases of disseminated primary varicella infection reported in the literature, 45, 46, [48] [49] [50] 55 one death occurred in a 26-year-old male patient with Crohn disease after a single infusion of infliximab (5 mg/kg). 47 
Epstein-Barr virus infection
epstein-Barr virus (eBv), also known as human herpesvirus (HHv)-4, is one of the most common human viruses, infecting as many as 95% of adults aged 35-40 years in the usa. 56 eBv causes infectious mononucleosis, Burkitt lymphoma, nasopharyngeal carcinoma and lPD. 36 the relationship between eBv and auto immune disease is not completely understood, although eBv has long been considered a possible cause of several autoimmune di seases. 57 antibodies to eBv are elevated in patients with ra, sle, reviewS or sjögren's syndrome. 58 a study by Balandraud et al. 59 reported that the viral load of eBv in the peri pheral blood was associated with high ra disease activity. However, neither methotrexate nor tnF bl ockers significantly modified eBv load over time. 59 several case reports in the literature have described associations between eBv-related conditions and tnF blockade. sari et al. 60 reported a case of a 20 year old male with juvenile ankylosing spondylitis who de veloped atypical infectious mononucleosis following 8 weeks of infliximab therapy. this patient presented with fatigue, malaise, abdominal discomfort, weight loss and lymphadeno pathy; however, fever, pharyngitis, and ly mphocytosis were not present. serologic test showed positive igm antibodies to the viral capsid antigen of eBv, which was confirmed by a lymph node biopsy. the authors concluded that tnF blockade might have masked the typical symptoms of infectious mono nucleosis. in a case report by Park et al. 61 a 65 year old Korean female with ra for 4 years developed multiple enlarged lymph nodes, elevated acute phase reactants and anemia several weeks after initiation of etanercept 25 mg twice-weekly. the patients was subsequently diagnosed with eBv-associated diffuse lPD, which gradually resolved after cessation of etanercept therapy. another case of eBv-associated lPD was reported in a 63 year old Japanese patient with ra following 1 month of treatment with inflixi mab 3 mg/kg. 62 in this patient, cessation of in fliximab therapy also resulted in a dramatic Almost all had an excellent clinical response in arthritis; CD4 + T cell counts and HIV viral loads remained stable; no serious infection was noted *Dosage not reported. Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HAART, highly active antiretroviral therapy; PsA, psoriatic arthritis; RA, rheumatoid arthritis. reviewS regression of lPD without further treatment. losco et al. 63 described a case of eBv-associated, diffuse, large B-cell lymphoma of the ileum after long-term azathioprine use and a single dose of infliximab (5 mg/kg) in a 42 year old male with Crohn disease. treatment with surgery and a course of chemotherapy resulted in a successful outcome. the use of tnF blockers is probably not the sole cause of eBv infection. nevertheless, cessation of these drugs should be considered when eBv infection is suspected, as they could indirectly increase the risk of infection or reactivation of eBv.
Cytomegalovirus infection
Cytomegalovirus, or HHv-5, is a common viral pathogen that infects 40-60% of the population in developed countries. 36, 64 several cases of cytomegalovirus infection complicating tnF blocking therapy have been reported (table 3) , of which four occurred in patients with inflammatory autoimmune disorders. [65] [66] [67] [68] in a case reported by Petersen et al., 66 a 37 year old male with a longstanding history of psoriasis and Psa developed a primary cytomegalovirus infection following 1 month of twice-weekly therapy with etanercept 50 mg (a standard initial dose for plaque psoriasis). Clinical presentations included fever, pneumonia, abnormal liver function tests, and otitis media. after discontinuation of etaner cept, the patient recovered sponta neously without antiviral therapy. six months later, he was restarted on etanercept without cytomegalovirus reactivation. Haerter et al. 65 reported a case of severe cyto megalovirus retinitis in the right eye of a 57 year old female with a longstanding history of ra who received infliximab (3 mg/kg) for 2 years. the initial episode of retinitis was treated with intra venous ganciclovir followed by maintenance therapy with oral valganci clovir therapy. Five weeks after stopping valganci clovir, however, she developed recurrent cytomegalovirus retinitis in the contralateral eye. a severe case of cytomegalovirus colitis was noted in a 25 year old male with Behçet disease following the third dose of infliximab (5 mg/kg). 68 this patient had previously been treated with monthly intravenous cyclophosphamide, interferon, ciclosporin and azathioprine. His colitis resolved with cessation of infliximab and treatment with intravenous ganciclovir for 1 month. in a study by Pontikaki et al., 67 of 151 patients with juvenile idiopathic arthritis (95 on etanercept and 56 on infliximab), one patient developed cytomegalovirus pulmonary infection follow ing in fliximab therapy.
as most of the patients in the studies listed in table 3 were on more than one immunosuppressive drug, it is reviewS difficult to determine whether the use of tnF bl ockers was directly involved in the development of cytomegalovirus infection. nonetheless, tnF blockade can theoretically put patients at an increased risk of cytomegalovirus infection.
Kaposi sarcoma-associated herpesvirus
Kaposi sarcoma, which is caused by HHv-6, is a vascular, multicentric malignant tumor. 69,70 its occurrence is rare and is usually associated with the presence of aiDs or organ transplantation. 71 a number of cases of Kaposi sarcoma have been noted in non-aiDs patients who are on immunosuppressive therapy for the treatment of rheumatic diseases such as ra, sle and vasculitis. [72] [73] [74] [75] limited data support an association between tnF blockade and Kaposi sarcoma, with only one case of Kaposi sarcoma reported in a patient with ra who received 12 doses of infliximab (3 mg/kg). 76 a prospective study of 60 patients with Crohn disease found no cases of HHv-6 during 14-weeks of tnF-blocking treatment, as measur ed by polymerase chain reaction (PCr) assay. 77 
HPV and MCV
although anogenital human papillomavirus virus (HPv) infection is the most common sexually transmitted disease in the usa, little is known about the incidence or prevalence of this infection in patients with rheumatic diseases. 78, 79 HPv types 1, 2, and 4 cause verrucae vulgaris, also known as benign warts, on the hands and feet. HPv types 6 and 11 usually cause benign condylomata acuminata, whereas types 16, 18, 31, and 33 cause precancerous cervical dysplasia and invasive carcinomas of the anogenital tract. the majority of infections with HPv are subclinical, and in 80% of cases the infection resolves spontaneously within 1 year as a result of a cellul ar immune response. 79 the risk of persistent HPv infection, particularly with oncogenic genotypes, might be associated with factors such as increased age, smoking, hormonal status, co existing infections and family history. 80 although there is no direct evidence linking the host immunologic response to a risk of HPv persistence, viral reactivation from a latent state in immunocompromised patients has been noted. 81, 82 an increased risk of cervical dys plasia, HPv infection and persistence has been repeatedly reported in patients following kidney, lung, and stem cell transplantation.
83-86 a study by Kane et al. 87 found that female patients with inflammatory bowel disease (iBD) exposed to immunosuppressive therapy were more likely to have abnormal cervical smears than healthy controls (odds ratio [or] 4.5, 95% Ci 1.5-12.3) or unexposed iBD patients (or 1.9, 95% Ci 1.1-12.1). 
Progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (Pml) is a rare, fatal demyelinating disease of the central nervous system. the incidence of Pml has increased with the aiDs pandemic and with the more widespread use of immunosuppressive drugs for organ transplantation or rheumatic disease therapy. 93 Pml is caused by reactivation of the JC virus, which is a type of polyomavirus. 94 up to may 2009, a total of 10 cases of Pml have been reported in patients taking natalizumab, a monoclonal antibody against α4 integrin that is used in the treatment of multiple sclerosis and Crohn disease. 95 ,96 the use of other monoclonal antibodies (efalizumab, rituximab and infliximab) and various transplant drugs such as tacrolimus and mycophenolate has been associated with the development of Pml.
97-100 a retrospective cohort study of 734 patients with iBD treated with infliximab showed that a fatal case of Pml occurred after the use of both natalizumab and infliximab. 101 Yamamoto et al. 102 reported a case of leukoencephalopathy in a 74 year old Japanese patient with ra taking etanercept. although this patient had characteristics associated with Pml such as altered mental status, seizure, and incontinence, the cerebrospinal fluid (CsF) was negative for JC virus Dna, as measured by PCr.
no cases of definite Pml following the use of etanerce pt or adalimumab have been reported. However, the diagnosis of Pml is easily missed without a high degree of suspicion. in some patients, features characteristic of the damage caused by Pml in the brain can be detected on mri scans. 93, 96 Pml can also be confirmed by quantitative PCr assay to detect JC virus Dna in the CsF or in a brain biopsy specimen. 93 the PCr test performed on the CsF has a sensitivity of 76-98% and a specificity of 98-99%. 103, 104 mohan et al. 105 reported a series of 19 patients with demyelinating neurologic events following treatment with tnF blockers (17 with etanercept and 2 with infliximab) for rheumatic diseases. none of the patients was diagnosed with Pml, but lumbar puncture was performed in only one patient and brain biopsy was done in just two patients. Jarand et al. 106 described three cases of neurological complications related to the use of infliximab, but with no specific information on the serology of JC virus. although JC virus infection is rare and might not be associated with tnF blockers, physicians should maintain a high level of suspicion in immunosuppressed patients with new onset of neurologic symptoms such as disorientation, ataxia, speech disturbance or visual loss.
Other viral-associated infections a few case reports have been published regarding viral pneumonia in patients who received tnF blocking therapy for chronic inflammatory diseases. smith et al. 107 reported that following etanercept therapy for ra, a 54 year old female developed severe para influenza type 3 pneumonia, which required mechanical ventilation and hospitalization for 3 weeks. 107 a case of severe adenovirus pneumonia following the first dose of infliximab (3 mg/kg) was reported in a 35 year old male with Crohn disease, 108 and Kang et al. 109 described a case of severe adenovirus pneumonia in a 55 year old female with ra who took etanercept 25 mg twice-weekly for 2 years. in both of these cases, the patient recovered after prolonged periods of hospitalization and treatment with antiviral agents and intravenous igG. most respiratory viral in fections are self-limited in immunocompetent reviewS individuals. the possibility of disseminated and fatal respiratory viral infection, however, should be con sidered in the differen tial diagnosis for immuno compromised patients to ensure that ap propriate treatments for these in fections are provided.
Vaccination against viral infection the appropriate vaccination of immunosuppressed patients, including those with rheumatic disease, is crucial to decrease morbidity and mortality related to infectious diseases (table 5) . in 2008, the american College of rheumatology (aCr) published their recommen dations for the use of nonbiologic and biologic DmarDs in ra. 110 the aCr task Force Panel recommended period ic pneumo coccal vaccinations and annual influenza vaccinations for all patients receiving DmarDs, and completion of a hepatitis B vaccination series for patients at risk of viral infection. these recommen dations are in accordance with the general recommendations of the us Centers for Disease Control and Prevention (CDC). 111 live-virus vaccines such as inhaled influenza and vZv vaccines are contra indicated in immunosuppressed patients. 110, 111 Based on the recommendations of the CDC advisory Committee on immunization Practices, patients with congenital immuno deficiency, hematologic malignancy, or general ized malignancy, or those undergoing therapy with alkylat ing agents, antimetabolites, radiation or highdose corticosteroids (at least 2 mg/kg of body weight or a total of 20 mg/day of prednisone), are considered severely immunocompromised. 111, 112 in patients with rheumatic disease who are on high-dose, systemic corticosteroids for more than 2 weeks, live-virus vaccination should be avoided during the therapy, although the vaccine can be given if steroid therapy has been stopped for at least 3 months. 111, 112 Patients receiving systemic corticosteroid therapy for less than 2 weeks, low-to-moderate doses of corticosteroids, local steroids injection, low-dose methotrexate (less than 0.4 mg/kg per week) or azathioprine (less than 3.0 mg/kg per day) can receive a live-virus vaccine. 112 nonetheless, physicians should determine the degree to which an individual patient is immunocompromised before administering a live-virus vaccine. statements from both the aCr task Force Panel and the aCr Hotline recom mend that live-virus vaccines, including vZv vaccine (see below), should be avoided in patients receiving biologic therapy. 110, 113 in some patients, the initiation of bio logic therapy can be delayed until at least 2 weeks after the zoster vaccine has been administered. 112 additionally, an inactivated, quadrivalent (types 6, 11, 16 and 18) HPv vaccine, Gardasil® (merck & Co., whitehouse station, nJ, usa), was approved for use in females aged 9-26 years. 78 this vaccine is most efficacious when given before the onset of sexual activity, but some benefit might exist in protecting against other genotypes even in patients with preexisting HPv infection. a recent clinical trial reported the efficacy of the quadrivalent HPv vaccine in women aged 25-45 years with no history of genital warts or cervical disease after 26 months of follow-up. 114 the composite endpoint comprised cervical or external genital disease or type-specific infection that had persisted for at least 6 months. owing to the lack of long-term studies, the duration of immunogenecity as well as the safety and effectiveness of this vaccine in immunosuppressed patients remain unknown. 115 Further studies examining the efficacy and safety of these newer vaccines in patients with immunocompromising conditions, including organ transplantation and immunosuppressive therapy for rheumatic diseases, are needed. 116 a reasonable approach could be to offer both immunizations to patients before the initiation of the immunosuppressive therapy, unless contra indicated according to the us CDC recommendations. 117 Conclusions tnF blockade seems to be associated with the occurrence of opportunistic infections, but associations between tnF blockers and most viral infections have not been systematically studied. the multitude of case reports in the literature, however, should raise suspicion for an association with viral infection in patients receiving these agents for the treatment of systemic inflammatory conditions. Given the existence of bias and confounding factors in observational studies and case series, systematic reviews and meta-analyses of randomized clinical trials might be able to provide better information on the poten tial links between tnF bl ockers and several viral infections, although the sample sizes and follow-up lengths could be prove problematic. inactivated viral vaccines are generally well-tolerated and safe even in immunocompromised patients. However, as noted in several studies with influenza and pneumo coccal vaccina tion, the antibody response in the setting of tnF blocking therapy might be altered depending on which agent is used, whether or not traditional DmarDs are used concomitantly, and the timing of vaccination in relation to the last dose of tnF blocker administered. 118, 119 Future research should evaluate the effectiveness and safety of viral vaccinations, as well as appro priate immuniza tion schedules in patients with rheumatic disease receiving immunosuppressives. nonetheless, vigil ant screening and selection of patients appropriate for immuniza tion with both inactivated and live-virus vaccines is required in routine clinical practice. rheumatologists should be aware of the potential for viral infection or reactivation in therapy with tnF bl ockers. education and close surveillance of patients on tnF blockers is critical for timely diagnosis and ma nagement of these potentially fatal infections.
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